Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).

P. J. Wiechno; P. Chlosta; J. Smok-Kalwat; J. Pikilel; D. H. Henry; D. F. Christianson; B. G. Somer; B. Mellado; I. Duran; D. E. Castellano; S. Callies; V. Andre; K. Hurt; M. M. F. Lahn; M. Stöckle; C. Reuter; B. Heinrich

doi:10.1200/jco.2011.29.15_suppl.4592

Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4592 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4592-4592 ◽

Cited By ~ 1

Author(s):

P. J. Wiechno ◽

P. Chlosta ◽

J. Smok-Kalwat ◽

J. Pikilel ◽

D. H. Henry ◽

...

Keyword(s):

Prostate Cancer ◽

Antisense Oligonucleotide ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Castrate Resistant Prostate Cancer ◽

Castrate Resistant ◽

Window Design ◽

First Line Treatment

Download Full-text

Comparison of first-line treatment options for metastatic castrate resistant prostate cancer: A retrospective cohort study

Annals of Oncology ◽

10.1093/annonc/mdx662.002 ◽

2017 ◽

Vol 28 ◽

pp. x77-x78

Author(s):

S. Pillai ◽

M.C. Semira ◽

C. Pezaro ◽

P. Parente ◽

B. Tran

Keyword(s):

Prostate Cancer ◽

Cohort Study ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Treatment Options ◽

Line Treatment ◽

First Line ◽

Castrate Resistant Prostate Cancer ◽

Castrate Resistant ◽

First Line Treatment

Download Full-text

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1389-7 ◽

2010 ◽

Vol 67 (4) ◽

pp. 927-933 ◽

Cited By ~ 15

Author(s):

Srikala S. Sridhar ◽

Christina M. Canil ◽

Kim N. Chi ◽

Sebastien J. Hotte ◽

Scott Ernst ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Antisense Oligonucleotide ◽

Phase Ii Study ◽

Line Treatment ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

First Line Treatment

Download Full-text

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

Cancer Medicine ◽

10.1002/cam4.3806 ◽

2021 ◽

Author(s):

Judith Passildas‐Jahanmohan ◽

Jean‐Christophe Eymard ◽

Mélanie Pouget ◽

Fabrice Kwiatkowski ◽

Isabelle Van Praagh ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology ◽

10.1016/j.eururo.2007.02.060 ◽

2007 ◽

Vol 52 (4) ◽

pp. 1020-1027 ◽

Cited By ~ 13

Author(s):

Giuseppe Di Lorenzo ◽

Riccardo Autorino ◽

Sisto Perdonà ◽

Michele De Laurentiis ◽

Massimo D'Armiento ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Line Treatment ◽

First Line ◽

Hormone Refractory ◽

First Line Treatment

Download Full-text

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX

Annals of Oncology ◽

10.1093/annonc/mdy287.024 ◽

2018 ◽

Vol 29 ◽

pp. viii381

Author(s):

J. Ham ◽

E. Meerten ◽

E. Fiets ◽

F. Jeurissen Mc Haaglanden ◽

M. Slingerland ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii Study ◽

Single Agent ◽

Line Treatment ◽

First Line ◽

Phase Ib ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 43

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 9

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text